PDE5A Antikörper (phosphorylated)
Kurzübersicht für PDE5A Antikörper (phosphorylated) (ABIN2750986)
Target
Alle PDE5A Antikörper anzeigenReaktivität
Wirt
Klonalität
Konjugat
Applikation
-
-
Bindungsspezifität
- AA 120-170, phosphorylated
-
Aufreinigung
- Affinity Purified
-
Immunogen
- Phosphorylated synthetic peptide common to all PDE5A variants taken within amino acid region 120-170 on human PDE5A protein.
-
Isotyp
- IgG
-
-
-
-
Beschränkungen
- Nur für Forschungszwecke einsetzbar
-
-
-
Format
- Liquid
-
Konzentration
- 1.0-1.25 μg/μL
-
-
-
: "Cytokine-induced S-nitrosylation of soluble guanylyl cyclase and expression of phosphodiesterase 1A contribute to dysfunction of longitudinal smooth muscle relaxation." in: The Journal of pharmacology and experimental therapeutics, Vol. 352, Issue 3, pp. 509-18, (2015) (PubMed).
: "Phosphodiesterase 1 regulation is a key mechanism in vascular aging." in: Clinical science (London, England : 1979), Vol. 129, Issue 12, pp. 1061-75, (2015) (PubMed).
: "Antenatal sildenafil treatment attenuates pulmonary hypertension in experimental congenital diaphragmatic hernia." in: Circulation, Vol. 123, Issue 19, pp. 2120-31, (2011) (PubMed).
: "Chronic hyperammonemia in vivo impairs long-term potentiation in hippocampus by altering activation of cyclic GMP-dependent-protein kinase and of phosphodiesterase 5." in: Journal of neurochemistry, Vol. 94, Issue 4, pp. 934-42, (2005) (PubMed).
-
: "Cytokine-induced S-nitrosylation of soluble guanylyl cyclase and expression of phosphodiesterase 1A contribute to dysfunction of longitudinal smooth muscle relaxation." in: The Journal of pharmacology and experimental therapeutics, Vol. 352, Issue 3, pp. 509-18, (2015) (PubMed).
-
- PDE5A (phosphodiesterase 5A, cGMP-Specific (PDE5A))
-
Andere Bezeichnung
- PDE5A
-
Pathways
- Regulation of G-Protein Coupled Receptor Protein Signaling
Target
-